Marketing authorisations granted for Bencium® in the Nordics

Consilient Health are proud to announce the grant of marketing authorisation for Bencium^® in Finland, in August 2019 following approvals earlier this year in Sweden and Norway. Bencium^® further expands the company’s endocrinology range and sits alongside Benferol^® which was launched in the Nordics in 2017.

Henrik Sahl, Consilient Health’s Country Manager for the Nordics commented, “Bencium^® is an important addition to our bone health range of products and meets a need identified by Nordic clinicians. The Consilient Health Nordic team are delighted to have received the marketing authorisation grants and looks forward to launching the product.”